The efficacy of paritaprevir and ombitasvir with a booster dose of ritonavir in genotype 1 HCV patients with hemodialysis
Not Applicable
- Conditions
- hemodialysis patients chronically infected with genotype 1 hepatitis C virus
- Registration Number
- JPRN-UMIN000022563
- Lead Sponsor
- Mitsui Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) patients who are allergic to paritaprevir, ombitasvir, or ritonavir. 2) patients with decompensated cirrhosis (Child-Pugh Class B or C) 3) pregnant women and women suspected of being pregnant 4) patients ineligible for some other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method antiviral effect (24 weeks after end of administration)
- Secondary Outcome Measures
Name Time Method 1) antiviral effect (4 weeks after end of administration) 2) the improvement of liver function at the end of treatment 3) adverse events
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How do paritaprevir and ombitasvir with ritonavir inhibit HCV NS3/4A and NS5A proteins in hemodialysis patients?
What is the efficacy of paritaprevir/ombitasvir plus ritonavir compared to sofosbuvir-based regimens in genotype 1 HCV hemodialysis patients?
Which biomarkers predict sustained virologic response to paritaprevir/ombitasvir in genotype 1 HCV patients on hemodialysis?
What are the adverse events associated with paritaprevir/ombitasvir and ritonavir in hemodialysis patients with HCV genotype 1?
How does the paritaprevir/ombitasvir/ritonavir regimen compare to glecaprevir/pibrentasvir in HCV genotype 1 patients with end-stage renal disease?